
Clinical data from patients treated under an investigational protocol for TPOXX (tecovirimat) support continuing to make the smallpox antiviral drug available to treat U.S. patients with monkeypox during the current outbreak, according to a report released today by the Centers for Disease Control and Prevention. The CDC protocol includes patient treatment and adverse event reporting forms to monitor safety and ensure intended clinical use.